
    
      The study sample will be randomized into three treatment arms, KD (Group A, n=50), Orlistat
      120 mg TID (Group B, n=50) and dietary and lifestyle counseling (Group C, n=50) in a 1:1:1
      ratio. Each arm will include 100% participants with obesity and co-morbid type 2 DM and 50%
      participants with co-morbid OSA. Randomization will be stratified for diabetic status.
    
  